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and the graft survival rate data was obtained from the
clinical studies of both drugs in Japan. 
RESULTS: Expected cost-effectiveness ratios per graft
surviving at 90 days were $13,730 ($1  120 Yen) for
mycophenolate mofetil, and $29,060 for muromonab
CD3 for the baseline analysis. Thus, a $12,400 cost-savings
of mycophenolate mofetil was observed. Comprehensive
sensitive analyses were done, such as drug efficacy rate in
the initial treatment, rejection rate after the initial treat-
ment, and graft loss rate. However, the cost-saving by my-
cophenolate mofetil continued to be found for all of these
cases so that the model can be considered to be robust. 
CONCLUSIONS: Mycophenolate mofetil treatment
proved to be cost-effective in comparison with muromonab
CD3 for intractable acute rejection in renal transplantation.
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OBJECTIVE: The purpose of this study was to analyze
the cost-utility ratios of liver and kidney transplantations
in a German transplant centre. 
METHOD: Sixty patients with liver transplantation and
77 patients with kidney transplantation were included in
a full cost assessment based on process costs with differ-
ent cost drivers (e.g., patient days, dialysis treatments,
admission) and based on the friction cost method to cal-
culate indirect costs. Benefits of transplantation were as-
sessed employing the EuroQol quality of life instrument
(German version). Both costs and benefits were dis-
counted with a discount rate of 5%. Several sensitivity
analyses were performed. 
RESULTS: Discounted with 5% and with a time horizon
of 20 years dialysis patients could gain 0.76 quality-
adjusted life-years (QALYs). Liver transplant recipients
gained 3.85 QALYs. The cost per QALYs gained ratio is
76,800 DM for liver transplantation. Gross cost per
QALY of dialysis patients is 147,800 DM (kidney trans-
plantation: 38,300 DM). Liver patients have a higher po-
tential to experience a significant gain in quality of life
than dialysis patients. On the other hand the long-term
results of patients who received a kidney transplantation
are better in terms of mortality compared to patients who
received a liver transplantation. Nevertheless, patients
with liver transplantation experience higher numbers of
QALYs gained than patients with kidney transplantation,
as the mortality of dialysis patients does not change after
transplantation (except for the operation risk). 
CONCLUSION: Liver transplantation is still a high-cost
procedure with a high cost-utility ratio compared to
other medical interventions. To avoid problems of fi-
nancing the cost of liver transplantation have to be de-
creased and/or outcomes (mortality, quality of life) must
be improved.
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Pain management guidelines advise opioids for the man-
agement of chronic moderate to severe pain, both malig-
nant and non-malignant. Among the options for opioid
therapy, oral opioids and transdermal fentanyl offer pa-
tient convenience and cost advantages over parenteral
(e.g., IV or IT) administration. After efficacy, patient con-
venience and cost are primary criteria in selecting chronic
pain control therapy. In order to better understand the
distinctions in these criteria, an economic framework for
evaluating transdermal fentanyl and oral opioids is
needed. 
OBJECTIVE: To develop an economic framework for
evaluating transdermal fentanyl and oral opioids for
management of chronic moderate to severe malignant
and non-malignant pain. 
METHODS: Based on a systematic review of the litera-
ture, a decision analytic model was developed. It is com-
prised of three phases: titration (lasting up to several
days), stabilization (30 days), and long-term use (through
the first year). The primary outcomes are costs, quality-
adjusted life-days (QALDs), and incremental cost-utility
ratios. Probabilities of events and disutility values were
determined from clinical trials of transdermal fentanyl,
controlled release morphine, and controlled release oxy-
codone, supplemented when necessary with expert opin-
ion. Costs were derived from publicly available data. 
RESULTS: The key cost drivers are opioid price, the
probability of switching to an alternative therapy, and
the cost of treating nausea and vomiting. The primary
parameters influencing QALDs are the probability of sus-
tained pain control and the probability and disutility of
chronic constipation. 
CONCLUSION: This model may be used to guide data
collection in head-to-head clinical trials, and may be used
by individual decision-makers to inform selection of the
optimal opioid for chronic pain management.
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OBJECTIVE: This study compares the impact of patient
education with individualized headache management on
health-related quality of life. 
